JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-08-13
DOI
10.1002/ijc.32624
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
- (2018) Marta Román et al. Molecular Cancer
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Afatinib restrains K-RAS–driven lung tumorigenesis
- (2018) Herwig P. Moll et al. Science Translational Medicine
- Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
- (2018) Na Luo et al. OncoImmunology
- Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer
- (2018) Mauricio S. Caetano et al. Nature Communications
- Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis
- (2017) Zuyao Yang et al. INTERNATIONAL JOURNAL OF CANCER
- Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo- inositol
- (2017) Nese Unver et al. INTERNATIONAL JOURNAL OF CANCER
- IL-6 and TNF-α promote metastasis of lung cancer by inducing epithelial-mesenchymal transition
- (2017) Guan-Sheng Shang et al. Oncology Letters
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Milestone Review on How Macrophages Affect Tumor Growth
- (2016) Christophe Caux et al. CANCER RESEARCH
- The JAK/STAT3 signalling pathway regulated angiogenesis in an endothelial cell/adipose-derived stromal cell co-culture, 3D gel model
- (2016) Changyue Xue et al. CELL PROLIFERATION
- An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer
- (2016) L. Girard et al. CLINICAL CANCER RESEARCH
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- (2016) Joshua D Campbell et al. NATURE GENETICS
- Clinical Implications of Genomic Discoveries in Lung Cancer
- (2016) Charles Swanton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
- (2016) Maxim V. Kuleshov et al. NUCLEIC ACIDS RESEARCH
- Heatmapper: web-enabled heat mapping for all
- (2016) Sasha Babicki et al. NUCLEIC ACIDS RESEARCH
- Inflammation as a driver and vulnerability of KRAS mediated oncogenesis
- (2016) Shunsuke Kitajima et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models
- (2016) Alessia Bottos et al. Nature Communications
- Tumor-Derived CXCL1 Promotes Lung Cancer Growth via Recruitment of Tumor-Associated Neutrophils
- (2016) Ming Yuan et al. Journal of Immunology Research
- Improving cancer immunotherapy by targeting the STATe of MDSCs
- (2016) Nienke de Haas et al. OncoImmunology
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams
- (2015) Henry Heberle et al. BMC BIOINFORMATICS
- Targeting JAK kinase in solid tumors: emerging opportunities and challenges
- (2015) M Buchert et al. ONCOGENE
- Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis
- (2015) Beatrice Grabner et al. Nature Communications
- Immunological Consequences of JAK Inhibition: Friend or Foe?
- (2015) Donal P. McLornan et al. Current Hematologic Malignancy Reports
- Targeting cytokine networks in KRAS-driven tumorigenesis
- (2014) Hadrien G Golay et al. Expert Review of Anticancer Therapy
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
- (2014) Z. Zhu et al. Cancer Discovery
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- (2013) Balázs Győrffy et al. PLoS One
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma
- (2012) Brendan D. Looyenga et al. PLoS One
- Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression
- (2011) Michel DuPage et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling
- (2011) L. Song et al. MOLECULAR CANCER THERAPEUTICS
- Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
- (2009) S. Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
- (2009) Michel DuPage et al. Nature Protocols
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More